Clinical trial
Single-Dose, Double-Blind, Crossover Study to Evaluate the Pharmacokinetic Comparability of ARALAST Fraction IV-1 Alpha1-Proteinase Inhibitor (ARALAST Fr. IV-1) and ARALAST
NCT00242385 is registered in ClinicalTrials.gov with Baxalta now part of Shire as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Single-Dose, Double-Blind, Crossover Study to Evaluate the Pharmacokinetic Comparability of ARALAST Fraction IV-1 Alpha1-Proteinase Inhibitor (ARALAST Fr. IV-1) and ARALAST
- Lead sponsor
- Baxalta now part of Shire
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- December 20, 2005
- Completion date
- June 5, 2006
- Enrollment
- 25 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.